Two important drugs -- AYUSH 82 and AYUSH SG -- developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) have been commercialised, a union minister informed Parliament on Friday.
"Drugs by the name AYUSH 82 for Type II Diabetes Mellitus and AYUSH SG for rheumatoid arthritis have been commercialised," Minister of State for AYUSH Shripad Yesso Naik said in a written reply in the Lok Sabha.
According to the minister, the Central Council for Research in Siddha (CCRS) has filed for patent of another drug, namely D5 Chooranam. The medicine is for treating Diabetes Mellitus.
The Central Council for Research in Homoeopathy has developed several drugs, including Coleus forskohlii, Catharanthus roseus, Cyclosporinum and Azathioprium, among others.
Drugs developed by the Central Council for Research in Unani Medicine (CCRUM) are for filariasis, hepatitis, ulcer, vitiligo and malaria. Patents have been filed for all the medicines developed by CCRUM.
"In addition, the Council of Scientific & Industrial Research (CSIR) also conducts research for development of herbal drugs and formulations. It has developed BGR-34 for diabetes, Risorine for tuberculosis and anti-arthritis formulation for osteoarthritis," Naik added.
--IANS
rup/nir/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app